An interventional study of Matter Neuroscience App and Stock Photos in Depression Mild, Depression and Depression Moderate, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Stanford University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Depression by Stanford University — 15 open to participants now, 17 under way, none of them phase 3. Depression · Stanford University.
Among the 77 studies in Depression by Stanford University, this one is the 5th largest by planned enrollment of the 64 interventional ones that give a count, is one of 4 that started in 2025, is one of 45 with no phase, reaches primary completion later than 6 of the 16 other live ones, and was the 68th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →15 of the 77 studies in Depression by Stanford University are open now, in 2 countries. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 5–14
Stanford University · Sites in United States
Ages 18–60
Stanford University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 65+
Stanford University · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 3 · Phase 4 5
First in 1999; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 40 across the 64 interventional studies, 87 across the 12 observational. Of the 53 that completed or were terminated, 17 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
9 of the studies in Depression by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06317636Stanford UniversityPropofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression | 2026-11 |
| NCT07188623Stanford UniversityVirtual Reality-Enhanced Behavioral Activation for Older Adults With Depression | 2026-12 |
| NCT04870255Stanford UniversityTreatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS | 2026-12 |
| NCT06430853Stanford UniversityPsychobiological Interventions in Pregnancy | 2027-01-01 |
| NCT06373718Stanford UniversitySleep Mechanisms Of Regulating Emotions | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 77 studies in Depression by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study will utilize an app, Matter Neuroscience, designed to help users with depression understand positive emotions and the neurotransmitters that create them. We hope to learn the safety and efficacy of neurofeedback for treating depression and lay the groundwork for a pivotal clinical trial.
The Matter Neuroscience application, available through the Apple App Store, is designed to help users understand positive emotions and the neurotransmitters that create them. The application allows users to collect good moments by adding photos and other information to the application and activating positive emotions when the photos and other information are viewed. When positive emotions are activated, the application allows users to quickly rate the positive emotions felt during moments. The data collected is translated into the user's Matter Score. Tracking the user's Matter Score can allow them to see how they are doing from the inside out. Neurotransmitter activity helps build neuroplasticity in the brain. Higher levels of neuroplasticity correlate with higher levels of creativity, intelligence, and empathy as well as longer, healthier, happier lifespans. The 7TMRI Scanner will be used to gather structural and functional brain data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No home training, no neurofeedback, no photos, no repeated scans
No home training no neurofeedback, repeated scans, personal photos
Device: Matter Neuroscience App · Other: No Home Training · Other: Personal Photos
No home training, neurofeedback, stock photos, repeated scans
Device: Matter Neuroscience App · Other: Stock Photos · Other: No Home Training
No home training, neurofeedback, personal photos, repeated scans
Device: Matter Neuroscience App · Other: No Home Training · Other: Personal Photos
Home training, no neurofeedback, stock photos, repeated scans
Device: Matter Neuroscience App · Other: Stock Photos · Other: Home Training
Home training, neurofeedback, stock photos, repeated scans
Device: Matter Neuroscience App · Other: Stock Photos · Other: Home Training
Home training, no neurofeedback, personal photos, repeated scans
Device: Matter Neuroscience App · Other: Personal Photos · Other: Home Training
Home training, neurofeedback, personal photos, repeated scans
Device: Matter Neuroscience App · Other: Personal Photos · Other: Home Training
An iPhone smartphone application
Stock Photos
No Home Training
Personal Photos
Home Training
Determine the safety and efficacy of neurofeedback for treating depression through MADRS scale changes
Determine the safety and efficacy of neurofeedback for treating depression through MADRS (Montgomery-Åsberg Depression Rating Scale) scale changes. The 9-item self-report version of the MADRS has an overall score range from 0-27, with higher scores corresponding to higher levels of depression.
Time frame: Screening, Baseline, Immediate Post, One Month Post, Three Month and Optional Six Month
Measure fMRI Change
Measure fMRI Change
Time frame: Baseline, Week 2, Week 4, Week 6, Immediate Post, Optional Three Month Post Scan
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 22 months is close to that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.